Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine significantly reduces levels of HIV RNA and HIV DNA rebound following ART interruption in a phase I/II randomized controlled clinical trial
Saved in:
Main Authors: | Erwann P. Loret (Author), Albert Darque (Author), Elvenn A. Loret (Author), Corinne Nicolino-Brunet (Author), Sophie Morange (Author), Elisabeth Castagnier (Author), Josiane Casanova (Author), Christine Caloustian (Author), Charléric Bornet (Author), Julie Coussirou (Author), Jihen Bousseta (Author), Bertrand Dussol (Author), Isabelle Ravaux (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2016-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Molecular characterisation of the inhibitor didehydro-Cortistatin A with the HIV-1 Tat protein
by: S. Mediouni, et al.
Published: (2017) -
An HIV-Tat inducible mouse model system of childhood HIV-associated nephropathy
by: Pingtao Tang, et al.
Published: (2020) -
Suppression of the HIV-1 reservoir with a potent Tat inhibitor
by: S. Valente, et al.
Published: (2015) -
Oxidative Stress Is Associated with Neuroinflammation in Animal Models of HIV-1 Tat Neurotoxicity
by: Jean-Pierre Louboutin, et al.
Published: (2014) -
Plasma and antibody glycomic biomarkers of time to HIV rebound and viral setpoint
by: M. Abdel-Mohsen, et al.
Published: (2019)